Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The Wave2 scaffold Hem-1 is required for transition of fetal liver hematopoiesis to bone marrow.

Shao L, Chang J, Feng W, Wang X, Williamson EA, Li Y, Schajnovitz A, Scadden D, Mortensen LJ, Lin CP, Li L, Paulson A, Downing J, Zhou D, Hromas RA.

Nat Commun. 2018 Jun 18;9(1):2377. doi: 10.1038/s41467-018-04716-5.

2.

NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.

Narayan S, Jaiswal AS, Sharma R, Nawab A, Duckworth LV, Law BK, Zajac-Kaye M, George TJ, Sharma J, Sharma AK, Hromas RA.

Oncotarget. 2017 Aug 1;8(34):57246-57264. doi: 10.18632/oncotarget.19778. eCollection 2017 Aug 22.

3.

Endonuclease EEPD1 Is a Gatekeeper for Repair of Stressed Replication Forks.

Kim HS, Nickoloff JA, Wu Y, Williamson EA, Sidhu GS, Reinert BL, Jaiswal AS, Srinivasan G, Patel B, Kong K, Burma S, Lee SH, Hromas RA.

J Biol Chem. 2017 Feb 17;292(7):2795-2804. doi: 10.1074/jbc.M116.758235. Epub 2017 Jan 3.

4.

Metnase Mediates Loading of Exonuclease 1 onto Single Strand Overhang DNA for End Resection at Stalled Replication Forks.

Kim HS, Williamson EA, Nickoloff JA, Hromas RA, Lee SH.

J Biol Chem. 2017 Jan 27;292(4):1414-1425. doi: 10.1074/jbc.M116.745646. Epub 2016 Dec 14.

5.

Interaction between APC and Fen1 during breast carcinogenesis.

Narayan S, Jaiswal AS, Law BK, Kamal MA, Sharma AK, Hromas RA.

DNA Repair (Amst). 2016 May;41:54-62. doi: 10.1016/j.dnarep.2016.04.003. Epub 2016 Apr 7. Review.

6.

The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis.

Chun C, Wu Y, Lee SH, Williamson EA, Reinert BL, Jaiswal AS, Nickoloff JA, Hromas RA.

Cell Cycle. 2016;15(7):957-62. doi: 10.1080/15384101.2016.1151585.

7.

EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.

Wu Y, Lee SH, Williamson EA, Reinert BL, Cho JH, Xia F, Jaiswal AS, Srinivasan G, Patel B, Brantley A, Zhou D, Shao L, Pathak R, Hauer-Jensen M, Singh S, Kong K, Wu X, Kim HS, Beissbarth T, Gaedcke J, Burma S, Nickoloff JA, Hromas RA.

PLoS Genet. 2015 Dec 18;11(12):e1005675. doi: 10.1371/journal.pgen.1005675. eCollection 2015 Dec.

8.

Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.

Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, Li MM, Slayton WB, Cogle CR.

Leuk Res Rep. 2015 Apr 3;4(1):24-7. doi: 10.1016/j.lrr.2015.03.002. eCollection 2015.

9.

Functional integration of acute myeloid leukemia into the vascular niche.

Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Masri AA, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH.

Leukemia. 2014 Oct;28(10):1978-1987. doi: 10.1038/leu.2014.109. Epub 2014 Mar 18.

10.

Trimming of damaged 3' overhangs of DNA double-strand breaks by the Metnase and Artemis endonucleases.

Mohapatra S, Yannone SM, Lee SH, Hromas RA, Akopiants K, Menon V, Ramsden DA, Povirk LF.

DNA Repair (Amst). 2013 Jun 1;12(6):422-32. doi: 10.1016/j.dnarep.2013.03.005. Epub 2013 Apr 18.

11.

Biochemical characterization of metnase's endonuclease activity and its role in NHEJ repair.

Beck BD, Lee SS, Williamson E, Hromas RA, Lee SH.

Biochemistry. 2011 May 24;50(20):4360-70. doi: 10.1021/bi200333k. Epub 2011 Apr 27.

12.

Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia.

Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA.

Am J Med. 2010 Aug;123(8):764.e1-9. doi: 10.1016/j.amjmed.2010.03.018.

13.

Human Pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair.

Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH.

J Biol Chem. 2008 Apr 4;283(14):9023-30. doi: 10.1074/jbc.M800150200. Epub 2008 Feb 8.

14.
15.

Biochemical characterization of a SET and transposase fusion protein, Metnase: its DNA binding and DNA cleavage activity.

Roman Y, Oshige M, Lee YJ, Goodwin K, Georgiadis MM, Hromas RA, Lee SH.

Biochemistry. 2007 Oct 9;46(40):11369-76. Epub 2007 Sep 18.

16.

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17763-8. Epub 2005 Nov 23.

17.

AML1-FOG2 fusion protein in myelodysplasia.

Chan EM, Comer EM, Brown FC, Richkind KE, Holmes ML, Chong BH, Shiffman R, Zhang DE, Slovak ML, Willman CL, Noguchi CT, Li Y, Heiber DJ, Kwan L, Chan RJ, Vance GH, Ramsey HC, Hromas RA.

Blood. 2005 Jun 1;105(11):4523-6. Epub 2005 Feb 10.

18.

Endothelial chemokines in autoimmune disease.

Christopherson KW 2nd, Hromas RA.

Curr Pharm Des. 2004;10(2):145-54. Review.

PMID:
14754394
19.

Update on late relapse of germ cell tumor: a clinical and molecular analysis.

George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung SH, Shen J, Finch DE, Kelley MR, Einhorn LH.

J Clin Oncol. 2003 Jan 1;21(1):113-22.

PMID:
12506179
20.

Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition.

Humphreys TL, Schnizlein-Bick CT, Katz BP, Baldridge LA, Hood AF, Hromas RA, Spinola SM.

J Immunol. 2002 Dec 1;169(11):6316-23.

21.

Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.

Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP Jr, Wood L, Cornetta K.

Clin Cancer Res. 2002 Nov;8(11):3383-93.

22.

Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases.

Christopherson KW 2nd, Hood AF, Travers JB, Ramsey H, Hromas RA.

Blood. 2003 Feb 1;101(3):801-6. Epub 2002 Sep 26.

23.

Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration.

Christopherson KW 2nd, Campbell JJ, Travers JB, Hromas RA.

J Pharmacol Exp Ther. 2002 Jul;302(1):290-5.

PMID:
12065729
24.

Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration.

Christopherson KW 2nd, Campbell JJ, Hromas RA.

Blood. 2001 Dec 15;98(13):3562-8.

25.
26.

Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.

Broun ER, Nichols CR, Gize G, Cornetta K, Hromas RA, Schacht B, Einhorn LH.

Cancer. 1997 Apr 15;79(8):1605-10.

PMID:
9118046
27.

Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features.

Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, Haskins S, Heerema NA, Gharpure V, Abonour R, Srour EF, Cornetta K.

Am J Clin Pathol. 1997 Apr;107(4):419-29.

PMID:
9124210
28.
29.

Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.

Broun ER, Wheat JL, Kneebone PH, Sundblad K, Hromas RA, Tricot G.

Antimicrob Agents Chemother. 1994 Mar;38(3):576-9.

30.

Absence of phorbol ester-induced down-regulation of myc protein in the phorbol ester-tolerant mutant of HL-60 promyelocytes.

Gailani D, Cadwell FJ, O'Donnell PS, Hromas RA, Macfarlane DE.

Cancer Res. 1989 Oct 1;49(19):5329-33.

31.

Decreased cisplatin uptake by resistant L1210 leukemia cells.

Hromas RA, North JA, Burns CP.

Cancer Lett. 1987 Aug;36(2):197-201.

PMID:
3621151
32.

Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.

Hromas RA, Andrews PA, Murphy MP, Burns CP.

Cancer Lett. 1987 Jan;34(1):9-13.

PMID:
3802072
33.

Anguidine potentiates cis-platinum in human brain tumor cells.

Hromas RA, Yung WK.

J Neurooncol. 1986;3(4):343-8.

PMID:
3958780
34.
35.

Bone marrow in the acquired immunodeficiency syndrome.

Hromas RA, Murray JL.

Ann Intern Med. 1984 Dec;101(6):877. No abstract available.

PMID:
6497203
36.

Flow cytometric analysis of the effect of ara-C on the chronobiology of bone marrow DNA synthesis.

Hromas RA, Hutchins JT, Markel DE, Scholes VE.

Chronobiologia. 1981 Oct-Dec;8(4):369-73.

PMID:
7327056
37.

Flow microfluorometric analysis of the cell cycle phase cytotoxicity of ARA-C.

Hromas RA, Markel DE, Scholes VE.

Res Commun Chem Pathol Pharmacol. 1980 Nov;30(2):365-8.

PMID:
7444164
38.

Oral roberts and objectivity.

Hromas RA.

Science. 1980 Jun 13;208(4449):1212. No abstract available.

PMID:
17830791

Supplemental Content

Loading ...
Support Center